Literature DB >> 2251022

Efficacy of tetracaine-adrenaline-cocaine topical anesthetic without tetracaine for facial laceration repair in children.

W A Bonadio1, V Wagner.   

Abstract

To determine whether the tetracaine component traditionally used in tetracaine-adrenaline-cocaine (TAC) is necessary to obtain effective topical anesthesia, a prospective study was performed to compare TAC and adrenaline-cocaine preparations for the repair of facial lacerations in children. Physicians were "blind" to which preparation was being used. Of 55 patients studied, 24 received TAC (103 sutures placed) and 31 received adrenaline-cocaine (151 sutures placed). The anesthetic efficacy of each preparation was approximately 95%; there were no adverse reactions related to administration of either medication or complications of wound healing noted in either group. The tetracaine component of TAC is superfluous for obtaining topical anesthesia of minor dermal lacerations of the face in children. The TAC formulation can be simplified by omitting tetracaine without compromising anesthetic efficacy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2251022

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  4 in total

1.  Topical anaesthesia for children's lacerations: an acceptable approach?

Authors:  J M Kendall; A Charters; S E McCabe
Journal:  J Accid Emerg Med       Date:  1996-03

Review 2.  Current guidelines for the treatment of acute pain in children.

Authors:  V Bhatt-Mehta
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 3.  Topical anaesthetics for pain control during repair of dermal laceration.

Authors:  Baraa O Tayeb; Anthony Eidelman; Cristy L Eidelman; Ewan D McNicol; Daniel B Carr
Journal:  Cochrane Database Syst Rev       Date:  2017-02-22

4.  Topical adrenaline and cocaine gel for anaesthetising children's lacerations. An audit of acceptability and safety.

Authors:  D W G Kennedy; Z Shaikh; M J Fardy; R J Evans; StJ V Crean
Journal:  Emerg Med J       Date:  2004-03       Impact factor: 2.740

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.